Disclosures for "Breakthrough AQP4-Positive NMOSD on Ravulizumab: Implications of Incomplete Complement Inhibition and Therapeutic Switching"
-
Dr. Garcia-Dominguez has received personal compensation for serving as an employee of Genentech.
-
Ms. Sleem has nothing to disclose.
-
Dr. Townley has nothing to disclose.
-
Dr. Lam has nothing to disclose.
-
Dr. Robers has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Robers has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Robers has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Robers has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Dr. Robers has received research support from Bristol Myers Squibb Foundation.